07.27.21
Archimica has started the operation of its expanded multi-purpose manufacturing capacity at its Lodi, Italy site.
A recent investment has added significantly to the company´s capabilities overall 170 m3 highly flexible reactor capacity to realize API and GMP Building Block custom process development and manufacturing projects from 10 kgs to multiple tons from September 2021 on. The investment comprises a range of reactor and separation equipment capabilities, with a total investment volume of $1.4 million.
“With this expansion and after the substantial investment in our laboratory capabilities earlier this year, we are now able to offer a further range of small to large volume multi-step custom manufacturing options applying Archimica´s unique chemical technology portfolio to the benefit of our customers worldwide. Archimica’s experienced and flexible team, our broad permit and state-of-the-art environmental protection facilities enable us to industrialize products and processes with the most challenging reagents and reactions known with short lead times to accelerate drug development and supply for complex multi-step APIs into all clinical and commercial stages,” said Ralf Pfirmann, executive chairman of Archimica.
A recent investment has added significantly to the company´s capabilities overall 170 m3 highly flexible reactor capacity to realize API and GMP Building Block custom process development and manufacturing projects from 10 kgs to multiple tons from September 2021 on. The investment comprises a range of reactor and separation equipment capabilities, with a total investment volume of $1.4 million.
“With this expansion and after the substantial investment in our laboratory capabilities earlier this year, we are now able to offer a further range of small to large volume multi-step custom manufacturing options applying Archimica´s unique chemical technology portfolio to the benefit of our customers worldwide. Archimica’s experienced and flexible team, our broad permit and state-of-the-art environmental protection facilities enable us to industrialize products and processes with the most challenging reagents and reactions known with short lead times to accelerate drug development and supply for complex multi-step APIs into all clinical and commercial stages,” said Ralf Pfirmann, executive chairman of Archimica.
